Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucoblock is a polyherbal dietary supplement formulated as a capsule, primarily utilized for the management of type 2 diabetes mellitus. It is characterized by its antidiabetic and antioxidant properties, which have been evaluated in preclinical models. Research indicates that Glucoblock effectively lowers fasting plasma glucose levels and improves insulin sensitivity, as evidenced by reductions in HOMA-IR values. Furthermore, the formulation exhibits significant antioxidant activity by increasing superoxide dismutase (SOD) levels and reducing total oxidant status (TOS) and oxidative stress index (OSI). The product typically contains a blend of botanical extracts, including Astragalus, Balsam Pear (Momordica charantia), Ginkgo Biloba, and Mulberry Leaf, which contribute to its phytochemical profile and therapeutic efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Glucoblock.